BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33141811)

  • 1. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
    Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
    Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
    Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
    Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
    Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
    [No Abstract]   [Full Text] [Related]  

  • 7. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.
    Cheng Y; Sun Z; Bai C; Yan X; Qin R; Meng C; Ying H
    Tumour Biol; 2016 Mar; 37(3):2863-9. PubMed ID: 26408184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
    Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
    Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
    Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
    Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
    Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
    J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
    Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
    Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
    PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
    van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
    Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms.
    Yu F; Fu J; Zhang C; Wu W; Ai S; Yao X; Meng Q; Huang Y; Lu G; Wang F; Qu W
    Pancreas; 2021 Jul; 50(6):882-889. PubMed ID: 34347728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
    PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
    Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
    Pulvirenti A; Rao D; Mcintyre CA; Gonen M; Tang LH; Klimstra DS; Fleisher M; Ramanathan LV; Reidy-Lagunes D; Allen PJ
    HPB (Oxford); 2019 May; 21(5):612-618. PubMed ID: 30366884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients.
    Chou WC; Hung YS; Hsu JT; Chen JS; Lu CH; Hwang TL; Rau KM; Yeh KY; Chen TC; Sun CF
    Neuroendocrinology; 2012; 95(4):344-50. PubMed ID: 22343505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.